Impact of Ciprofol Versus Propofol on Heart Injury After Video-Assisted Thoracoscopic Surgery in Adults Aged 45 to 80

What this Trial Is About

Researchers are evaluating the effects of Ciprofol, a new intravenous anesthetic drug, on myocardial injury occurring after non-cardiac thoracic surgery. Myocardial injury after noncardiac surgery MINS is identified by elevated cardiac troponin levels due to ischemic causes and is a common complication after thoracic surgery, linked to increased risks of mortality and vascular problems. This study aims to see if Ciprofol can reduce the incidence of MINS compared to propofol, focusing on patients undergoing video-assisted thoracoscopic surgery VATS for lung cancer treatment. Participants will be randomly assigned to receive either Ciprofol or propofol as sedative agents during general anesthesia for VATS. Both groups will also receive sufentanil and cis-atracurium intravenously. The doses and administration times for study drugs are carefully controlled. The trial is double-blind and multicenter, comparing the circulatory stability and sedative effects of Ciprofol with those of propofol in thoracic surgery patients. During the study, patients will be monitored for myocardial injury within 30 days post-surgery, as well as for new heart rhythm problems, episodes of low blood pressure, and mortality rates. Data on anesthesia induction, maintenance, and perioperative hemodynamics will be collected. The study includes baseline assessments and safety monitoring, with follow-up visits lasting at least three days postoperatively. Researchers will analyze the incidence of myocardial injury and other cardiovascular outcomes to assess the impact of Ciprofol on patient safety and recovery.

Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery in Video-Assisted Thoracoscopic Surgery